statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on ACELYRIN, INC. (SLRN Research Report), reducing the price target to $28.00. Em...

ACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy Rating

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023.
The post SLRN Stock...

SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Acelyrin reports FY23 EPS ($5.43), consensus ($7.40)

Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with...

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Avalo acquires Phase 2-ready anti-IL-1 mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private...

Avalo Acquires Anti-IL-1  mAb and Announces Private Placement Financing of up to $185 Million

Acelyrin announces phase 1/2 proof-of-concept data for lonigutamab

Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024...

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Acelyrin Inc options imply 7.3% move in share price post-earnings

Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis Robust clinical...

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 Deep and...

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Volume	1.14M
52-Wk High	$29.88
52-Wk Low	$4.14

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.96	--	--	N/A
Q4'23	-$0.99	$4.45	551.35%	BEAT
Q3'23	-$0.47	-$0.87	-86.70%	MISSED
Q2'23	-$0.76	-$0.40	47.54%	BEAT
Q1'23	-$0.88	-$8.61	-884.00%	MISSED

SLRN Acelyrin Inc

About

Feed

News

Sentiment

Earnings

Fundamentals